

Open-label study that included patients who were randomized to ADA or placebo in the CHARM trial were followed-up for 2 years. **Upon entry in ADHERE all patients randomized to placebo in CHARM and still receiving blinded placebo received OL adalimumab therapy eow.**

#### Primary outcome:

Maintenance of remission and clinical response w36 and w60 in ADHERE (these weeks correspond to 92 and 116 weeks since CHARM trial start)

#### Results: \*when referring to placebo means placebo during CHARM not during ADHERE

- Clinical remission w36 (92w from CHARM), 36% placebo vs 41.5% ADA eow vs 52.1% ADAew.
- Clinical remission w60 (116w from CHARM) 37.6%, 41.9% and 49.8% of patients on placebo,, adalimumab eow and adalimumab weekly, respectively.
- Remission rates for patients on combination therapy with immunosuppressant 64.2% vs ADA alone 60.2%, p=ns

#### Conclusions:

Adalimumab demonstrated sustained maintenance of clinical remission, improvements in quality of life and reductions in hospitalization during longterm treatment for CD, with no new safety concerns identified

### Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease

